NCT05487066 is a clinical trial in Venous Thromboembolism, sponsored by Lijuan Zhang.

Who is sponsoring NCT05487066?

NCT05487066 is sponsored by Lijuan Zhang.

What condition does NCT05487066 study?

NCT05487066 studies Venous Thromboembolism.

Is NCT05487066 still recruiting?

NCT05487066 is currently completed. Last updated 8 May 2024.

Last reviewed 2024-05-08 · How we verify

NCT05487066

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of ICU-VTE Scale in ICU Patients

Completed Last updated 8 May 2024

What this trial tests

trial in Venous Thromboembolism in 269 participants. Completed in 10 December 2023.

Timeline

1 May 2022

Primary endpoint
10 December 2023

10 December 2023

Quick facts

Lead sponsor	Lijuan Zhang
Status	Completed
Study type	OBSERVATIONAL
Enrollment	269
Start date	1 May 2022
Primary completion	10 December 2023
Estimated completion	10 December 2023
Sites	1 location across China

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →

Sponsor

Lijuan Zhang

Who can join

18 and older, any sex, with Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Venous thromboembolism (VTE) is a common cause of morbidity and mortality among critically ill patients. No uniform standard model of VTE risk for critically ill patients was formatted by now. In 2020, Viarasilpa et al. developed the ICU⁃VTE rating table, mainly for ICU patients. However, it lacks validation. We examined and compared how well the ICU-VTE score predict and stratify VTE risk in comprehensive ICU patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

External Validation of the ICU-Venous Thromboembolism Risk Assessment Model in Adult Critically Ill Patients.
Zhang L, Chen F, Hu S, Zhong Y, et al · · 2024 · cited 1× · PMID 39215513 · DOI 10.1177/10760296241271406

Verify or expand the search:

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05487066 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lijuan Zhang
Last refreshed: 8 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05487066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing